title: n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease.
abstract: DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on telomere length was studied in a double-blind placebo-controlled trial in CKD. Eighty-five CKD patients were randomized to: n-3 fatty acids (4 g); CoQ (200 mg); both supplements; or control (4 g olive oil), daily for 8 weeks. Telomere length was measured in neutrophils and peripheral blood mononuclear cells (PBMC) at baseline and 8 weeks, with and without correction for cell counts. Main and interactive effects of n-3 fatty acids and CoQ on telomere length were assessed adjusting for baseline values. F₂-isoprostanes were measured as markers of oxidative stress. There was no effect of n-3 fatty acids or CoQ on neutrophil or PBMC telomere length. However, telomere length corrected for neutrophil count was increased after n-3 fatty acids (p = 0.015). Post-intervention plasma F₂-isoprostanes were negative predictors of post-intervention telomere length corrected for neutrophil count (p = 0.025).The effect of n-3 fatty acids to increased telomere length corrected for neutrophil count may relate to reduced oxidative stress and increased clearance of neutrophils with shorter telomeres from the circulation. This may be a novel mechanism of modifying CVD risk in CKD patients.
authors.affiliation: School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000, Western Australia, Australia. anne.barden@uwa.edu.au.
authors.forename: Anne
authors.initials: A
authors.lastname: Barden
authors.affiliation: CSIRO Food and Nutrition, Adelaide 5000, South Australia, Australia. nathan.OCallaghan@csiro.au.
authors.forename: Nathan
authors.initials: N
authors.lastname: O'Callaghan
authors.affiliation: School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000, Western Australia, Australia. valerie.burke@uwa.edu.au.
authors.forename: Valerie
authors.initials: V
authors.lastname: Burke
authors.affiliation: School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000, Western Australia, Australia. emilie.mas@sa.gov.au.
authors.forename: Emile
authors.initials: E
authors.lastname: Mas
authors.affiliation: School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000, Western Australia, Australia. lawrie.beilin@uwa.edu.au.
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Beilin
authors.affiliation: CSIRO Food and Nutrition, Adelaide 5000, South Australia, Australia. Michael.Fenech@csiro.au.
authors.forename: Michael
authors.initials: M
authors.lastname: Fenech
authors.affiliation: Department of Nephrology and Transplantation, Fiona Stanley Hospital, Murdoch 6150, Western Australia, Australia. Ashley.Irish@health.wa.gov.au.
authors.forename: Ashley B
authors.initials: AB
authors.lastname: Irish
authors.affiliation: School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000, Western Australia, Australia. gerald.watts@uwa.edu.au.
authors.forename: Gerald F
authors.initials: GF
authors.lastname: Watts
authors.affiliation: School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000, Western Australia, Australia. ian.puddey@uwa.edu.au.
authors.forename: Ian B
authors.initials: IB
authors.lastname: Puddey
authors.affiliation: Telethon Kids Institute, Subiaco 6008, Western Australia, Australia. Rae-Chi.Huang@telethonkids.org.au.
authors.forename: Rae-Chi
authors.initials: RC
authors.lastname: Huang
authors.affiliation: School of Medicine and Pharmacology, Royal Perth Hospital, University of Western Australia, Perth 6000, Western Australia, Australia. trevor.mori@uwa.edu.au.
authors.forename: Trevor A
authors.initials: TA
authors.lastname: Mori
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D019587:Dietary Supplements / Q000009:adverse effects; D004281:Docosahexaenoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D028441:F2-Isoprostanes / Q000097:blood; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D016615:Telomere / Q000187:drug effects* / Q000378:metabolism; D059505:Telomere Homeostasis / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D014451:Ubiquinone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014904:Western Australia
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D004338:Drug Combinations; D028441:F2-Isoprostanes; D014451:Ubiquinone; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C405603:Omacor; C024989:coenzyme Q10
keywords: coenzyme Q10; n-3 fatty acids; neutrophils; oxidative stress; telomere length